|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||85.40 - 85.40|
|52 Week Range||78.78 - 95.00|
|Beta (5Y Monthly)||0.55|
|PE Ratio (TTM)||19.73|
|Forward Dividend & Yield||3.35 (3.87%)|
|Ex-Dividend Date||Mar 08, 2022|
|1y Target Est||N/A|
Positive opinion could expand the role of Cosentyx® (secukinumab) in reducing flare risk in pediatric enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) patients in the EUSafety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indicationsSince its initial approval, Cosentyx has a proven sustained efficacy profile across several systemic inflammatory conditions and has treated more than 700,000 patients worldwide 1-11 Ba
Pharmaceutical companies including Novartis and Roche have teamed up with global cancer organisations in an alliance aimed at getting more oncology medications to poorer countries. Currently, fewer than 50% of the cancer drugs on the World Health Organization's (WHO) essential medicines list are available in low and middle income countries, and the disease burden is growing. Without action, almost three in four cancer deaths are set to occur in these settings in the next decade.
Alnylam's (ALNY) portfolio of approved drugs is witnessing strong uptake so far while its pipeline is progressing well. However, stiff competition in the target market remains a woe.